Comparative Study of Racemic Salbutamol and Levosalbutamol in patients with Bronchial Asthma

Raadhika, K (2007) Comparative Study of Racemic Salbutamol and Levosalbutamol in patients with Bronchial Asthma. Masters thesis, Madurai Medical College, Madurai.


Download (1MB) | Preview


Bronchial Asthma is known for time immemorial. Variety of therapeutic agents though available in different systems of medicine, modern scientific medicine try to act at the cellular level to some extent with constraints. Among the modern pharmacological agents use for bronchial asthma, salbutamol is included in the WHO’s essential drug list. However, the available form is in racemic form with inherent side effects. A newly available oral form such as levosalbutamol (R-salbutamol) is shown to have better than conventional one. Hence, the present study was undertaken 1. To compare the efficacy and tolerability of Racemic salbutamol and Levosalbutamol. 2. To identify the side effects of each, and to recommend the appropriate one. After the institutional ethical clearance and informed consent, a single blind open label randomized comparative trial was attempted among 50 (25 in each group), mild bronchial asthma patients who satisfied a rigid inclusion and exclusion criteria. Their socio demographic, clinical, and laboratory data were collected. They were trained, counselled and explained about the study and were given respective salbutamol orally after food. Subjective and Objective assessment (using PEFR) were made along with side effects. The data were analysed statistically. There were 11 males and 14 females in racemic salbutamol group, and 10 males and 15 females in levosalbutamol group. The age ranged from 25 to 40 in racemic salbutamol group, and 23 to 39 years in levosalbutamol group. The BMI of both groups varied from 19 to 23 and the mean was 21. They had episodes of wheezing over a period of 5 years, there hematology, bio chemical tests, liver function test, renal function test, X-ray, ECG were nil contributory. The patients were grouped into those receiving racemic salbutamol as group I and those receiving levosalbutamol as group II. The mean PEFR before and after therapy in group I was 249.6 and 265.2 respectively, and the mean in group II was 254.8 and 309.6 respectively. The pulmonary function improved significantly (Table 8) after oral exposure to salbutamol irrespective of the type. However the improvement was very high in the levosalbutamol group (p=0.0000175), thus indicating the levosalbutamol has better effect as bronchodilator. Side effects were negligible in levosalbutamol group. There was no gross alteration in serum potassium level after therapy. In view of the efficacy, tolerability and significant improvement in PEFR with negligible side effects observed among levosalbutamol group, it is recommended that oral levosalbutamol can be used for those with mild bronchial asthma.

Item Type: Thesis (Masters)
Uncontrolled Keywords: Racemic Salbutamol, Levosalbutamol, Bronchial Asthma, Comparative study.
Subjects: MEDICAL > Pharmacology
Depositing User: Subramani R
Date Deposited: 12 May 2018 17:15
Last Modified: 23 Aug 2020 14:14

Actions (login required)

View Item View Item